JP2012126725A5 - - Google Patents

Download PDF

Info

Publication number
JP2012126725A5
JP2012126725A5 JP2012004614A JP2012004614A JP2012126725A5 JP 2012126725 A5 JP2012126725 A5 JP 2012126725A5 JP 2012004614 A JP2012004614 A JP 2012004614A JP 2012004614 A JP2012004614 A JP 2012004614A JP 2012126725 A5 JP2012126725 A5 JP 2012126725A5
Authority
JP
Japan
Prior art keywords
net
corresponding amount
neta
estradiol
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012004614A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012126725A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012126725A publication Critical patent/JP2012126725A/ja
Publication of JP2012126725A5 publication Critical patent/JP2012126725A5/ja
Withdrawn legal-status Critical Current

Links

JP2012004614A 2003-09-29 2012-01-13 Ｈｒｔ製剤 Withdrawn JP2012126725A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200301408 2003-09-29
DKPA200301408 2003-09-29
US50996203P 2003-10-09 2003-10-09
US60/509,962 2003-10-09
DKPA200301828 2003-12-10
DKPA200301828 2003-12-10
US53612104P 2004-01-13 2004-01-13
US60/536,121 2004-01-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006529642A Division JP2007506796A (ja) 2003-09-29 2004-09-21 Ｈｒｔ製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015002288A Division JP2015110604A (ja) 2003-09-29 2015-01-08 Ｈｒｔ製剤

Publications (2)

Publication Number Publication Date
JP2012126725A JP2012126725A (ja) 2012-07-05
JP2012126725A5 true JP2012126725A5 (cg-RX-API-DMAC7.html) 2013-04-18

Family

ID=37524840

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006529642A Pending JP2007506796A (ja) 2003-09-29 2004-09-21 Ｈｒｔ製剤
JP2012004614A Withdrawn JP2012126725A (ja) 2003-09-29 2012-01-13 Ｈｒｔ製剤
JP2015002288A Withdrawn JP2015110604A (ja) 2003-09-29 2015-01-08 Ｈｒｔ製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006529642A Pending JP2007506796A (ja) 2003-09-29 2004-09-21 Ｈｒｔ製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015002288A Withdrawn JP2015110604A (ja) 2003-09-29 2015-01-08 Ｈｒｔ製剤

Country Status (10)

Country Link
US (1) US20060281721A1 (cg-RX-API-DMAC7.html)
EP (2) EP1670440B1 (cg-RX-API-DMAC7.html)
JP (3) JP2007506796A (cg-RX-API-DMAC7.html)
AU (1) AU2004275469B2 (cg-RX-API-DMAC7.html)
DK (1) DK1670440T3 (cg-RX-API-DMAC7.html)
ES (1) ES2482104T3 (cg-RX-API-DMAC7.html)
IL (1) IL175843A0 (cg-RX-API-DMAC7.html)
PL (1) PL1670440T3 (cg-RX-API-DMAC7.html)
PT (1) PT1670440E (cg-RX-API-DMAC7.html)
WO (1) WO2005030175A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202007019049U1 (de) 2007-11-05 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Verwendung eines Gestagens in Kombination mit einem Estrogen zur Prophylaxe der Laktoseintoleranz bei der oralen Kontrazeption
EP2127643A1 (de) * 2008-05-30 2009-12-02 Bayer Schering Pharma Aktiengesellschaft Orale Pelletformulierungen mit zeitversetzter Wirkstofffreigabe
US20130137664A1 (en) 2010-04-15 2013-05-30 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10413504B2 (en) * 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
SMT201800232T1 (it) 2015-06-18 2018-07-17 Mithra Pharmaceuticals S A Unita' di dosaggio orodispersibile contenente un componente di estetrolo
LT3310333T (lt) 2015-06-18 2020-06-25 Estetra Sprl Burnoje dirperguojama vaisto formą, turinti estetrolio komponentą
PT3310345T (pt) 2015-06-18 2021-05-28 Estetra Sprl Comprimido orodispersível contendo estetrol
SI3310346T1 (sl) 2015-06-18 2021-07-30 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4826831A (en) 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
AU582540B2 (en) * 1983-08-05 1989-04-06 Pre Jay Holdings Ltd. A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor
US4530839A (en) * 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
CZ289081B6 (cs) * 1994-09-22 2001-10-17 Akzo Nobel N. V. Způsob výroby farmaceutické lékové formy a tableta
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
US5897880A (en) * 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US5928666A (en) * 1996-11-12 1999-07-27 Cygnus Inc. Crystalline form of estradiol and pharmaceutical formulations comprising same
IL128818A0 (en) * 1998-03-12 2000-01-31 Akzo Nobel Nv Making dosage units using low shear granulation
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
US6667050B1 (en) * 1999-04-06 2003-12-23 Galen (Chemicals) Limited Chewable oral contraceptive
DE10100911A1 (de) 2001-01-11 2002-08-01 Schering Ag Verfahren zur Hormonersatztherapie und dessen Darreichungsform
US6962908B2 (en) * 2001-12-21 2005-11-08 Warner Chilcott Company Inc. Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
US20040185093A1 (en) * 2003-03-18 2004-09-23 Szymczak Christopher E. Compositions containing sucralose
US20040265373A1 (en) * 2003-06-27 2004-12-30 David Wynn Soft tablet containing high molecular weight cellulosics

Similar Documents

Publication Publication Date Title
JP2012126725A5 (cg-RX-API-DMAC7.html)
NL301341I2 (nl) eplontersen, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301238I2 (nl) Deucravacitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301245I2 (nl) Ritlecitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301161I2 (nl) zanubrutinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301155I2 (nl) abrocitinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
JP2013014622A5 (cg-RX-API-DMAC7.html)
NL301149I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301006I2 (nl) Lorlatinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
NL301326I2 (nl) imetelstat, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
EP2811994A4 (en) PHARMACEUTICAL COMPOSITIONS WITH DIMETHYLFUMARATE
IL222738A0 (en) Pharmaceutical emulsion composition comprising progestogen
JP2012205928A5 (cg-RX-API-DMAC7.html)
JP2012107057A5 (cg-RX-API-DMAC7.html)
JP2015503422A5 (cg-RX-API-DMAC7.html)
EP2616076A4 (en) PHARMACEUTICAL COMPOSITIONS
HUE046559T2 (hu) Policiklusos karbamoilpiridon vegyületek és gyógyszerészeti alkalmazásuk
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
PT2940014T (pt) Derivado 2,3-di-hidro-isoindol-1-ona como supressor da quinase btk e composição farmacêutica incluindo o mesmo
JP2014530840A5 (cg-RX-API-DMAC7.html)
BR112015004936A2 (pt) composição farmacêutica revestida contendo regorafenib
EP2758052A4 (en) PHARMACEUTICAL COMPOSITIONS
JP2015525757A5 (cg-RX-API-DMAC7.html)
EP2827866A4 (en) PHARMACEUTICAL COMPOSITIONS WITH BENZYL ALCOHOL
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament